Expert Review of Neurotherapeutics最新文献

The differential diagnosis of autism spectrum disorder in adults. 成人自闭症谱系障碍的鉴别诊断。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-09 DOI: 10.1080/14737175.2025.2490533

Hannah M Carroll, Robyn P Thom, Christopher J McDougle

{"title":"The differential diagnosis of autism spectrum disorder in adults.","authors":"Hannah M Carroll, Robyn P Thom, Christopher J McDougle","doi":"10.1080/14737175.2025.2490533","DOIUrl":"https://doi.org/10.1080/14737175.2025.2490533","url":null,"abstract":"Introduction: Diagnosing autism spectrum disorder (ASD) in adults is challenging due to its heterogeneity and symptom overlap with other conditions. Making an accurate diagnosis can be difficult and overwhelming but is vital for proper accommodations and interventions while avoiding unproductive or harmful treatments.Areas covered: The authors have based their review on a comprehensive literature search using PubMed, PsycINFO, and Google Scholar to identify relevant recommendations, diagnostic tools, and common differential diagnoses for adults with ASD. A clinical framework is provided based on the DSM-5 criteria, starting with an evaluation of childhood symptom onset and persistent manifestations of the core criteria - social and communication impairment, along with restricted, repetitive behaviors. Conditions with overlapping presentations, including personality disorders, anxiety, depression, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, and schizophrenia, are discussed, as well as challenges in differentiating these from ASD.Expert opinion: Many factors complicate diagnosing ASD in adults - such as skewed public perception or misinformation spread on social media. Existing tools frequently miss subtle or atypical presentations, particularly in underdiagnosed groups like women and older adults. Promising advances in machine learning and artificial intelligence will hopefully improve diagnostic precision in the future. Up-to-date clinician training and large-scale research remain paramount for refining adult ASD diagnosis.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in endovascular thrombectomy for the treatment of acute ischemic stroke. 血管内取栓治疗急性缺血性脑卒中的研究进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-09 DOI: 10.1080/14737175.2025.2490538

David Lauer, Jakub Sulženko, Hana Malíková, Ivana Štětkářová, Petr Widimský

{"title":"Advances in endovascular thrombectomy for the treatment of acute ischemic stroke.","authors":"David Lauer, Jakub Sulženko, Hana Malíková, Ivana Štětkářová, Petr Widimský","doi":"10.1080/14737175.2025.2490538","DOIUrl":"https://doi.org/10.1080/14737175.2025.2490538","url":null,"abstract":"Introduction: Acute ischemic stroke (AIS) is the second leading cause of death and one of the leading causes of long-term disability globally. Endovascular thrombectomy (EVT) has revolutionized treatment for large vessel occlusion (LVO), providing 20% increase in post-stroke functional independence compared to intravenous thrombolysis (IVT) alone. Despite its proven efficacy, EVT is underutilized. While it is suitable for at least 15-20% of AIS patients, its mean adoption ranges from less than 1% to 7% in different areas.Areas covered: This review highlights key findings from pivotal randomized controlled trials and real-world data, focusing on patient selection criteria, advancements in thrombectomy devices, and procedural innovations. A comprehensive literature search was performed using PubMed, Scopus, EMBASE and the Cochrane Library for relevant randomized controlled trials and observational studies.Expert opinion: Disparity in access to EVT requires strategic investments in healthcare systems and international multidisciplinary collaboration. Enhancing geographic coverage with thrombectomy-capable centers and optimizing prehospital triage systems are essential. Bridging the gap between treatment capability and real-world implementation is critical to improving global AIS outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking the potential of virtual reality for post-stroke sensorimotor rehabilitation - are we any closer? 释放虚拟现实在中风后感觉运动康复中的潜力——我们离目标更近了吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-08 DOI: 10.1080/14737175.2025.2490535

Mindy F Levin, Jeroen B J Smeets

引用次数: 0

Two decades of metacognitive training for psychosis: successes, setbacks, and innovations. 二十年来治疗精神病的元认知训练：成功、挫折和创新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-06 DOI: 10.1080/14737175.2025.2483204

Steffen Moritz, Ryan P Balzan, Mahesh Menon, Kim M Rojahn, Merle Schlechte, Ruth Veckenstedt, Daniel Schöttle, Antonia Meinhart

{"title":"Two decades of metacognitive training for psychosis: successes, setbacks, and innovations.","authors":"Steffen Moritz, Ryan P Balzan, Mahesh Menon, Kim M Rojahn, Merle Schlechte, Ruth Veckenstedt, Daniel Schöttle, Antonia Meinhart","doi":"10.1080/14737175.2025.2483204","DOIUrl":"10.1080/14737175.2025.2483204","url":null,"abstract":"Introduction: Schizophrenia is among the most debilitating mental health conditions. While antipsychotic medication represents the primary pillar of treatment, guidelines now also recommend psychotherapy. Metacognitive Training (MCT) has emerged over the past 20 years as a novel approach that addresses the cognitive biases involved in the pathogenesis of schizophrenia. MCT seeks to enhance patients' awareness of their cognitive distortions and reduce overconfidence. MCT is available in individual and group formats.Areas covered: This review provides a comprehensive overview of MCT, detailing its theoretical foundations, development, and implementation. The authors present meta-analyses demonstrating its efficacy in improving positive symptoms as well as negative symptoms and self-esteem. Lastly, the review covers the integration of the COGITO app to support MCT. For our narrative review we searched data bases including PubMed, Web of Science, EMBASE, PsycINFO, and MEDLINE.Expert opinion: MCT represents a significant advance in the treatment of schizophrenia, offering a flexible, low-threshold intervention that can be easily implemented in various clinical settings. The training's focus on metacognitive processes provides patients with tools to understand and manage their symptoms. Future research should seek to develop shortened as well as more personalized versions and investigate the long-term sustainability of the effects.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy? 降低胆固醇治疗阿尔茨海默病的策略：希望还是谬误？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-03 DOI: 10.1080/14737175.2025.2483928

Katia Azarfar, Boris Decourt, Brandon Sanchez Camacho, John Joshua Lawrence, Tania R Omondi, Marwan N Sabbagh

{"title":"Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?","authors":"Katia Azarfar, Boris Decourt, Brandon Sanchez Camacho, John Joshua Lawrence, Tania R Omondi, Marwan N Sabbagh","doi":"10.1080/14737175.2025.2483928","DOIUrl":"10.1080/14737175.2025.2483928","url":null,"abstract":"Introduction: As the world population ages, Alzheimer disease (AD) prevalence increases. However, understanding of AD etiology continues to evolve, and the pathophysiological processes involved are only partially elucidated. One compound suspected to play a role in the development and progression of AD is cholesterol. Several lines of evidence support this connection, yet it remains unclear whether cholesterol-modifying strategies have potential applications in the clinical management of AD.Areas covered: A deep literature search using PubMed was performed to prepare this narrative review. The literature search, performed in early 2024, was inclusive of literature from 1990 to 2024. After providing an overview of cholesterol metabolism, this study summarizes key preclinical studies that have investigated cholesterol-modifying therapies in laboratory models of AD. It also summarizes past and current clinical trials testing specific targets modulated by anti-cholesterol therapies in AD patients.Expert opinion: Based on current epidemiological and mechanistic studies, cholesterol likely plays a role in AD etiology. The use of cholesterol-modifying therapies could be a promising treatment approach if administered at presymptomatic to early AD phases, but it is unlikely to be efficient in mild, moderate, and late AD stages. Several recommendations are provided for hypercholesterolemia management in AD patients.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing impulse control and related behavioral disorders in Parkinson's disease: where we are in 2025? 管理帕金森病的冲动控制和相关行为障碍：2025年我们在哪里？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-02 DOI: 10.1080/14737175.2025.2485337

Leonardo Rigon, Carmelo Fogliano, K Ray Chaudhuri, Karolina Poplawska-Domaszewicz, Cristian Falup-Pecurariu, Iulia Murasan, Mirjam Wolfschlag, Per Odin, Angelo Antonini

{"title":"Managing impulse control and related behavioral disorders in Parkinson's disease: where we are in 2025?","authors":"Leonardo Rigon, Carmelo Fogliano, K Ray Chaudhuri, Karolina Poplawska-Domaszewicz, Cristian Falup-Pecurariu, Iulia Murasan, Mirjam Wolfschlag, Per Odin, Angelo Antonini","doi":"10.1080/14737175.2025.2485337","DOIUrl":"10.1080/14737175.2025.2485337","url":null,"abstract":"Introduction: Impulse control and related behavioral disorders (ICBDs) commonly complicate Parkinson's disease (PD) course. The ICBDs spectrum encompasses two groups of conditions, with distinct pathophysiology: proper 'impulse control disorders (ICDs)' (e.g. gambling) and the 'ICDs related disorders (ICDs-RD)' (e.g. punding). Behavioral disturbances are associated with dopamine replacement therapies. ICBDs affect quality of life of patients and caregivers, making their management essential for reducing PD overall burden.Areas covered: This article reviews current management strategies for ICBDs in PD. The authors highlight strengths and limitations of these strategies, and explore the potential role of emerging treatment options, giving particular focus to new compounds and invasive therapies.Expert opinion: Prevention, close monitoring, and caregiver involvement are essential in managing ICBDs in PD. Treatment approaches should be tailored to ICBDs' functional impact and aimed to reduce the pulsatile stimulation of dopamine receptors, especially D2. Dopamine agonist (DA) tapering remains the primary therapeutic approach, alongside psychotherapy and second-line agents, like atypical antipsychotics and serotonin-noradrenaline reuptake inhibitors. Insights into ICDs pathophysiology and DA-specific pharmacodynamics indicate safer profiles for certain preparations (e.g. rotigotine patches) and possibly for D1/D5 agonists like tavapadon. Invasive treatments, including deep brain stimulation and infusion therapies, should be prioritized in advanced-stage PD complicated by ICBDs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-18"},"PeriodicalIF":3.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Charcot-Marie-Tooth disease: a review of clinical developments and its management - What's new in 2025? 乳齿赘肉病：临床发展及其管理综述——2025年有什么新发现？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1080/14737175.2025.2470980

Amedeo De Grado, Marina Serio, Paola Saveri, Chiara Pisciotta, Davide Pareyson

{"title":"Charcot-Marie-Tooth disease: a review of clinical developments and its management - What's new in 2025?","authors":"Amedeo De Grado, Marina Serio, Paola Saveri, Chiara Pisciotta, Davide Pareyson","doi":"10.1080/14737175.2025.2470980","DOIUrl":"10.1080/14737175.2025.2470980","url":null,"abstract":"Introduction: Charcot-Marie-Tooth disease (CMT) understanding and diagnostic rates are improving. Symptomatic management is still the only option, but many therapeutic approaches are under investigation, some in the clinical trial phase.Areas covered: Through a comprehensive search in PubMed, the ClinicalTrials.gov website, and the latest abstracts on the topic, the authors review the diagnostic advances and promising treatments, focusing on pharmacological and gene therapy/silencing approaches, and on clinical trial challenges. They also review current CMT management, including rehabilitation, orthotics, and associated symptoms and comorbidities.Expert opinion: The CMT field is evolving rapidly, with significant advances in genetic diagnosis and disease recognition. International networks and patient organization partnerships are vital for progress, enabling collaboration and large-scale studies. Metabolic neuropathies are relatively easier to target, and interim analysis results from the CMT-SORD trial suggest govorestat may become the first approved CMT drug. Gene therapy shows promise but currently faces safety and targeting challenges; PMP22 silencers for CMT1A are close to being tested in patients. New drugs, such as HDAC6 inhibitors, are also approaching the clinical trial phase, despite existing hurdles. Supportive care, including rehabilitation and orthotics, continues to improve quality of life. There is optimism that within the next decade, approved therapies will reduce disease burden.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"427-442"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review. 激光间质热治疗在立体定向放射手术后复发性脑转移瘤：系统回顾。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-02-27 DOI: 10.1080/14737175.2025.2471551

Timoteo Almeida, Jheremy S Reyes, Sydney E Scanlon, Stephen C Frederico, Sakibul Huq, Costas G Hadjipanayis

{"title":"Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review.","authors":"Timoteo Almeida, Jheremy S Reyes, Sydney E Scanlon, Stephen C Frederico, Sakibul Huq, Costas G Hadjipanayis","doi":"10.1080/14737175.2025.2471551","DOIUrl":"10.1080/14737175.2025.2471551","url":null,"abstract":"Introduction: Laser Interstitial Thermal Therapy (LITT) has emerged as a promising minimally invasive treatment option for recurrent brain metastases, especially for patients who have previously undergone Stereotactic Radiosurgery (SRS). Despite its growing use, additional research is needed to explore its utility and safety in this population.Methods: This systematic review evaluates the literature on LITT for recurrent brain metastases post-SRS, including patient selection, treatment protocols, outcomes, and complications. The review was registered with PROSPERO (CRD42024577899) and followed the PRISMA 2020 guidelines.Results: Seventeen studies, encompassing 694 patients, met our inclusion criteria. The median overall survival (OS) across these studies was 14.4 months with an average 12-month OS of 60.1%. Notably, median OS was 5.9 months after LITT alone and 12.7 months when LITT was followed by adjuvant SRS. The pooled local control rate was 75.6% at 6 months and 72.2% at 12 months.Conclusion: LITT is a minimally invasive treatment option that has shown potential in managing recurrent brain metastases after prior SRS, particularly when biopsy is required to differentiate between tumor recurrence and radiation necrosis. However, data on the comparative efficacy and cost-effectiveness of LITT versus alternative treatments such as repeat SRS or craniotomy remain limited.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"465-475"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The utility of magnetoencephalography in epilepsy and its implications for treatment. 脑磁图在癫痫中的应用及其治疗意义。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-02-22 DOI: 10.1080/14737175.2025.2470333

Samuel Molot-Toker, James T Rutka, Eisha Christian

引用次数: 0

A comprehensive update on neuroimaging endpoints in amyotrophic lateral sclerosis. 肌萎缩性侧索硬化症神经影像学终点的全面更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI: 10.1080/14737175.2025.2470324

Massimo Filippi, Alma Ghirelli, Edoardo Gioele Spinelli, Federica Agosta

{"title":"A comprehensive update on neuroimaging endpoints in amyotrophic lateral sclerosis.","authors":"Massimo Filippi, Alma Ghirelli, Edoardo Gioele Spinelli, Federica Agosta","doi":"10.1080/14737175.2025.2470324","DOIUrl":"10.1080/14737175.2025.2470324","url":null,"abstract":"Introduction: There are currently few treatments approved for amyotrophic lateral sclerosis (ALS). Additionally, there remains a significant unmet need for reliable, standardized biomarkers to assess endpoints in clinical trials. Magnetic resonance imaging (MRI)- and positron emission tomography (PET)-derived metrics could help in patient selection and stratification, shortening trial duration and reducing costs.Areas covered: This review focuses on the potential use of neuroimaging endpoints in the context of ALS therapeutic trials, providing insights on structural and functional neuroimaging, plexus and muscle alterations, glial involvement and neuroinflammation, envisioning how these surrogates of disease progression could be implemented in clinical trials. A PubMed search covering the past 15 years was performed.Expert opinion: Neuroimaging is essential in understanding ALS pathophysiology, aiding in disease progression tracking and evaluating therapeutic interventions. High costs, limited accessibility, lack of standardization, and patient tolerability limit their use in routine ALS care. Addressing these obstacles is essential for fully harnessing neuroimaging potential in improving diagnostics and treatment in ALS.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"397-413"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0